vida: extract claims from 2026-05-03-clinical-trial-vanguard-glp1-psychiatric-both-directions

- Source: inbox/queue/2026-05-03-clinical-trial-vanguard-glp1-psychiatric-both-directions.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: The apparent contradiction between protective (Swedish cohort) and harmful (pharmacovigilance) psychiatric signals reflects real population-level heterogeneity, not methodological artifact
+confidence: experimental
+source: Clinical Trial Vanguard Psych Pulse synthesis, 2026-04-01
+created: 2026-05-03
+title: GLP-1 psychiatric effects are directionally opposite in metabolic versus psychiatric disease patients — protective in metabolic cohorts but potentially harmful in severe psychiatric comorbidity with concurrent psychotropic use
+agent: vida
+sourced_from: health/2026-05-03-clinical-trial-vanguard-glp1-psychiatric-both-directions.md
+scope: causal
+sourcer: Clinical Trial Vanguard
+related: ["clinical-ai-bias-amplification-creates-compounding-disparity-risk-at-scale", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
+---
+
+# GLP-1 psychiatric effects are directionally opposite in metabolic versus psychiatric disease patients — protective in metabolic cohorts but potentially harmful in severe psychiatric comorbidity with concurrent psychotropic use
+
+The GLP-1 psychiatric safety paradox resolves through population stratification rather than dismissing either signal. Clinical trials and cohort studies systematically exclude patients with 'psychiatric instability' — specifically those with substance use disorders, prior mood episodes, or active anhedonia. This creates a bifurcated evidence base: (1) Trial/cohort populations over-represent metabolically driven psychiatric patients where GLP-1 appears protective (Swedish cohort showing reduced depression/anxiety in metabolic disease context), and (2) Pharmacovigilance captures real-world deployment including psychiatric comorbidity patients where GLP-1 may worsen symptoms. The highest-risk subpopulation is patients on concurrent psychotropic medications (antidepressants, benzodiazepines) showing OR 4.07-4.45 for suicidality reporting. The Novo Nordisk semaglutide MDD program (interim data late 2026) will provide the first prospective RCT evidence in psychiatric patients rather than metabolic patients with psychiatric comorbidities, serving as the decisive test of whether GLP-1 is genuinely antidepressant or whether the metabolic patient finding is a selection effect. The eating disorder signal is consistent with this framework: GLP-1 appetite suppression may trigger pathology in vulnerable patients systematically excluded from trials but present in real-world deployment.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-23-glp1-substance-use-disorder-33-trials.md
 scope: causal
 sourcer: PubMed/ClinicalTrials.gov systematic review
 challenges: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
-related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"]
 supports: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery"]
 reweave_edges: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24"]
 ---
@@ -67,3 +67,10 @@ NCT06548490 is the first Phase 2 RCT testing semaglutide for treatment-refractor
 **Source:** Hendershot et al., JAMA Psychiatry 2025
 
 First RCT evidence: 26-week trial of 108 AUD+obesity patients showed semaglutide+CBT reduced heavy drinking days 41.1%, with NNT 4.3 versus 7+ for approved AUD medications. Blood-alcohol biomarkers corroborated self-reports. However, a separate cohort study found 195% increased MDD risk with GLP-1 agonists, requiring psychiatric screening.
+
+
+## Challenging Evidence
+
+**Source:** Clinical Trial Vanguard 2026-04-01
+
+Concurrent psychotropic medication use (antidepressants, benzodiazepines) shows OR 4.07-4.45 for suicidality in GLP-1 users, suggesting the dopaminergic mechanism may interact adversely with psychiatric medications rather than uniformly benefiting substance use disorder patients. The protective AUD signal may be specific to metabolic disease + AUD comorbidity rather than primary psychiatric AUD.

domains/health/glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms.md

@@ -10,17 +10,17 @@ agent: vida
 scope: causal
 sourcer: "Circulation: Heart Failure (AHA Journals)"
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
-supports:
+supports: ["GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport"]
-- GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
+related: ["acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef", "GLP-1 receptor agonist weight loss and side effects are partially genetically determined with GLP1R and GIPR variants predicting 6-20% weight loss range and up to 14.8-fold variation in tirzepatide-specific vomiting risk", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "glp1-cardiac-benefits-weight-independent-via-fibrosis-attenuation"]
-related:
+reweave_edges: ["acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef|related|2026-04-12", "GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport|supports|2026-04-12", "GLP-1 receptor agonist weight loss and side effects are partially genetically determined with GLP1R and GIPR variants predicting 6-20% weight loss range and up to 14.8-fold variation in tirzepatide-specific vomiting risk|related|2026-04-27"]
-- acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef
-- GLP-1 receptor agonist weight loss and side effects are partially genetically determined with GLP1R and GIPR variants predicting 6-20% weight loss range and up to 14.8-fold variation in tirzepatide-specific vomiting risk
-reweave_edges:
-- acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef|related|2026-04-12
-- GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport|supports|2026-04-12
-- GLP-1 receptor agonist weight loss and side effects are partially genetically determined with GLP1R and GIPR variants predicting 6-20% weight loss range and up to 14.8-fold variation in tirzepatide-specific vomiting risk|related|2026-04-27
 ---
 
 # GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss
 
 GLP-1 receptors are expressed directly in heart, blood vessels, kidney, brain, adipose tissue, and lung. The review identifies multiple weight-independent mechanisms: direct GLP-1R-mediated cardiomyocyte protection, anti-fibrotic effects in cardiac tissue, anti-inflammatory signaling in cardiac macrophages, and improved renal sodium handling independent of weight changes. This mechanistic framework explains the STEER study finding where semaglutide showed 29-43% lower MACE than tirzepatide in matched ASCVD patients despite tirzepatide being superior for weight loss. The key distinction is that tirzepatide's GIPR agonism adds metabolic benefit but may not add cardiovascular benefit beyond GLP-1R effects alone. This suggests the GLP-1R-specific cardiac mechanism is the primary driver of cardiovascular benefit, not the weight loss itself. The therapeutic implication is that non-obese HFpEF patients may benefit from GLP-1RAs through these weight-independent mechanisms, and lower doses that minimize appetite suppression while preserving GLP-1R cardiac signaling might provide cardiovascular benefit while reducing sarcopenia risk from excessive lean mass loss.
+
+## Challenging Evidence
+
+**Source:** Clinical Trial Vanguard 2026-04-01
+
+The eating disorder and malnutrition signal (12-14% nutritional deficiency rate) suggests GLP-1's appetite suppression mechanism may create competing risks: cardiovascular protection through inflammation reduction versus nutritional compromise through excessive appetite suppression, particularly in patients with psychiatric vulnerability to eating pathology.

inbox/archive/health/2026-05-03-clinical-trial-vanguard-glp1-psychiatric-both-directions.md

@@ -7,10 +7,13 @@ date: 2026-04-01
 domain: health
 secondary_domains: []
 format: analysis
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-03
 priority: medium
 tags: [GLP-1, psychiatric-safety, mental-health, methodology, indication-bias, selection-bias, eating-disorders]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content